Abstract
To the Editor: We appreciate the comments from Jourde-Chiche and Daugas1 on our study evaluating the frequency of renal flares in patients with proliferative lupus nephritis in whom the dose of mycophenolate mofetil (MMF) was reduced during remission maintenance therapy. They raise the question whether hydroxychloroquine (HCQ) cotreatment can influence the observed flare rates. An association of HCQ withdrawal with exacerbations of renal disease in patients with lupus has been described by Tsakonas, et al 2 … Address correspondence to Dr. Laskari; E-mail: katerina_laskari{at}yahoo.gr
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
